



The Precision
Peptide Company

GSE: BPC · OTCQB: PNGAF

INVESTOR PRESENTATION · AUGUST 2026

Peptides, *reimagined.*

Engineering the next generation of human performance —
clinical-grade peptides, delivered without needles.



A massive shift is happening in human health — and peptides sit at its centre.

THE GLP-1 WAVE

\$157B

Projected global GLP-1 market by 2030 — up from \$53.5B in 2024. Ozempic and Wegovy made "peptide" a household word.

Grand View Research, 2025

MAINSTREAM ADOPTION

25M

Americans forecast to be on GLP-1 therapy by 2030 — 2.5× today. A generation is being trained to use peptides daily.

J.P. Morgan Global Research, 2026

THE LONGEVITY MOVEMENT

\$6.8T

Global wellness economy in 2024, forecast to reach \$9.8T by 2029. Optimization culture — from podcasts to telehealth — has moved peptides from niche forums to the mainstream.

Global Wellness Institute, 2025 Monitor

Sources: (1) Grand View Research, *GLP-1 Receptor Agonist Market* — US\$53.5B (2024) to a projected US\$156.71B (2030), CAGR 17.46%: [grandviewresearch.com](https://www.grandviewresearch.com). (2) J.P. Morgan Global Research, obesity drugs — approximately 25 million Americans on GLP-1 treatment by 2030, up from around 10 million in 2025: jpmorgan.com/insights/global-research/current-events/obesity-drugs. (3) Global Wellness Institute, *Global Wellness Economy Monitor 2025* — US\$6.8 trillion (2024), projected US\$9.8 trillion by 2029: globalwellnessinstitute.org. Third-party market estimates as at their respective publication dates; not Company projections — see forward-looking statements.

Demand is growing. *Delivery has not kept up.*

Invasive injections

Most peptides still require syringes — a hard stop for the mainstream consumer.

Cold-chain logistics

Refrigeration, reconstitution and mixing make distribution costly and fragile.

A regulatory grey zone

Compounding channels leave consumers uncertain about quality, sourcing and compliance.



• LAUNCHED · ON SALE NOW

No needles. No mixing. *Just apply.*

The Recovery Patch delivers BPC-157 through a wearable, pre-measured transdermal format — clinical-grade peptides, without the friction that keeps consumers out.

AS FEATURED IN **Men'sHealth**

10 single-use patches per pack

Pre-measured dose

No cold storage

US-made · LegitScript-certified



We don't just sell molecules — *we own the delivery layer.*

1

Stabilization

A temperature-stable matrix preserves peptide integrity — no refrigeration, no reconstitution, no waste.

2

Permeation

Absorption enhancers carry the compound through the stratum corneum — the skin barrier that defeats ordinary topicals.

3

Sustained release

Micro-dosed delivery over the wear period, designed for steadier availability than a single bolus.



PLATFORM, NOT PRODUCT

The same proprietary matrix extends across the pipeline — from recovery peptides today to metabolic compounds in development.

95.5%

Chromatographic purity of the BPC-157 Recovery Patch, verified by an independent third-party laboratory — clearing the $\geq 95\%$ pharmaceutical-industry benchmark.

2.02 mg per patch

Precisely dosed, pre-measured delivery.

US cGMP manufactured

Made in approved United States facilities.

Third-party tested

Traceable, compliant formulations — quality a consumer can verify.

Chromatographic purity (95.5%) and content (2.02 mg per patch) per independent third-party laboratory analysis of the BPC-157 Recovery Patch, as reported in the Company's news release dated August 19, 2026, available under the Company's profile on SEDAR+ at www.sedarplus.ca.





Seven products. One standard: *precision.*

On the market today — US-made, third-party tested, LegitScript-certified.



Ageless

Epitalon + NMN

Cellular energy & vitality†



Blue

Methylene Blue

Focus & memory†



BPC

BPC-157

Recovery & gut health†



Chill

Pineal + DHH-B

Relaxation & sleep†



KPV

KPV tripeptide

Gut balance & recovery†



Hair

GHK-Cu + Zinc Thymulin

Scalp & follicle support†



+ The Recovery Patch — the flagship

BPC-157 transdermal · 10 single-use patches · no syringes, no mixing

†Label structure/function statements. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

One patch platform. *A pipeline of molecules.*

• LAUNCHED · ON SALE NOW

The Recovery Patch

BPC-157 · 2.02 mg per patch

20,000-unit production run received July 2026. Featured in Men's Health. 95.5% purity independently verified.



IN TESTING · TARGETED Q3/Q4 2026

TA-1 Immunity Patch

Thymosin Alpha-1

A first-to-market immune-support patch — Thymosin Alpha-1 in a portable, needle-free format with no mixing and no cold storage.

IN DEVELOPMENT · ANNOUNCED AUG 2026

GLP-1 Patch

Tirzepatide

A needle-free tirzepatide format pointed at the US\$62–66B global GLP-1 market — a growing category in medicine.

The TA-1 Immunity Patch and Tirzepatide GLP-1 Patch are development-stage products; there is no assurance of completion or commercialization — see forward-looking statements. Global GLP-1 market size of US\$62–66B per Grand View Research, *GLP-1 Receptor Agonist Market* (US\$66.4B, 2025): [grandviewresearch.com](https://www.grandviewresearch.com); also cited in the Company's news release dated August 19, 2026, on SEDAR+ at www.sedarplus.ca.

Precision dosing, *in your pocket.*

The Casetides™ Peptide Pen pairs a replaceable 5 ml cartridge system with pharmacy-grade peptide vials — physician-prescribed through the Company's nationwide telehealth platform and compounded 100% in the United States.

All 50 states

telehealth & pharmacy fulfillment

503A US compounding

up to ~25,000 prescriptions/day capacity

LegitScript certified

independent compliance seal

Launch targeted

announced August 2026 — see FLS



GLP-1
RX ONLY



Sermorelin
RX ONLY



NAD+
RX ONLY

Prescription products dispensed only pursuant to a valid prescription following consultation with a licensed provider.

Prescription-grade. *Compounded in America.*

Every prescription product is prescribed by a licensed provider through the Company's nationwide telehealth platform and compounded 100% in the United States — a pharmacy supply chain patients and investors can verify.



LegitScript-certified · 503A-regulated US compounding



Tirzepatide
RX ONLY



Semaglutide
RX ONLY



Sermorelin
RX ONLY



NAD+
RX ONLY

1 Prescribed
Licensed-provider consultation through telehealth — all 50 states.

2 Compounded
In a US 503A partner pharmacy — capacity up to ~25,000 prescriptions per day.

3 Delivered
LegitScript-certified operations shipping direct to patients nationwide.

Regulation is clearing the grey market. Demand keeps compounding. *Nobody owns the delivery layer yet.*

Regulatory clarity

U.S. regulators are moving against grey-zone compounded peptides — rewarding companies built compliant from day one.

Behavioural shift

Consumers moved from reactive treatment to proactive optimization — and expect consumer-grade convenience.

Open category

No trusted consumer brand yet owns needle-free peptide delivery. That is the position TPPC is taking.

A once-a-decade collision of *markets*.

TPPC operates where three vast markets overlap: validated peptide science, the supplement economy, and the global wellness movement — selling consumer formats of a molecule class supported by a growing body of clinical evidence.

Sources: Global Wellness Institute, *Global Wellness Economy Monitor 2025* — wellness economy US\$6.8T (2024): globalwellnessinstitute.org. Grand View Research, *Dietary Supplements Market* — US\$209.5B (2025): grandviewresearch.com/industry-analysis/dietary-supplements-market-report. Grand View Research, *Peptide Therapeutics Market* — US\$140.9B (2025): grandviewresearch.com/industry-analysis/peptide-therapeutics-market. Grand View Research, *GLP-1 Receptor Agonist Market* — projected US\$156.71B by 2030: grandviewresearch.com/press-release. Third-party market estimates as at their respective publication dates; not Company projections — see forward-looking statements.

Global wellness economy

The cultural tide

\$6.8T

Dietary supplements

The retail channel

\$209B

Peptide therapeutics

The science engine

\$140B+

GLP-1 segment by 2030

~3x from 2024 · the accelerant

\$157B

Recurring revenue, built on *trust*.

Direct-to-consumer

High-margin sales on our own platform — all customers now consolidated on the Company's website.

Subscription

30-day patch supplies create natural replenishment cycles and compounding lifetime value.

Omnichannel

Retail and partner distribution — anchored by the MMA.INC audience partnership.

B2B licensing

Future licensing of the proprietary delivery matrix to pharma and consumer-health players.

THE MOAT

In a category defined by grey-market distrust, the defensible asset is legitimacy: US cGMP manufacturing, third-party testing, physician-guided formulation — a brand consumers don't have to gamble on.

MMA.INC

Five million fight fans. *One exclusive partner.*

TPPC is the exclusive peptide partner across the MMA.INC ecosystem — MixedMartialArts.com, BJJLink, TrainAlta and Hype — 22 countries of the most recovery-obsessed athletes in sport. From year two, 75% of every partnership dollar flows to TPPC.



John Kavanagh
Co-founder · Conor
McGregor's coach



**Conor
McGregor**
Strategic
investor



**Donald
Trump Jr.**
Strategic
investor



**Laura
Sanko**
Non-
executive
director

5M+

social followers

530K

user profiles

18,000

gyms on platform · 800+
verified

75/25

revenue share to TPPC
from year two

Exclusive strategic marketing
agreement · signed May 8, 2026

75K+ active students
training on platform

Every product: US-made ·
LegitScript-certified

MMA.INC ecosystem figures and revenue-share terms per the Exclusive Strategic Marketing Agreement with Mixed Martial Arts Group Limited dated May 8, 2026 and information provided by MMA.INC; see the Company's news release of that date on SEDAR+ at www.sedarplus.ca. Individuals shown are principals, investors or directors of MMA.INC, not spokespersons for the Company. Images used with permission.

Execution, on the *public record*.

May 2026	Exclusive MMA.INC marketing partnership signed — access to a global combat-sports audience across 22 countries.
May 2026	95.5% purity independently verified — third-party lab confirms the BPC-157 patch clears the $\geq 95\%$ industry benchmark.
Jul 2026	Nationwide retail opens days after FDA panel backs six peptides — seven products in stock, all 50 states; four of the backed peptides already in TPPC formulations.
Aug 2026	All commerce consolidated on the Company platform — Amino Innovations store and customers migrated to precisionpeptidecompany.com .
Aug 2026	Peptide Pen launch targeted — expanding the US-made delivery platform.
Aug 2026	Needle-free Tirzepatide patch development announced — pointing the platform at the GLP-1 category.

16×


REVENUE GROWTH IN FIVE YEARS

The GLP-1 era is likely only the *opening act* of the peptide wave.

The playbook: **hims**

NYSE: HIMS

~\$6.7B market cap · 2.5M+ subscribers · revenue per public filings



+69% revenue in the first full year after adding GLP-1 weight loss — mainstream GLP-1 demand converts straight into consumer-platform growth.

DEC 2025 → APR 2026 · FDA

The first two oral GLP-1s approved, four months apart — both sold through telehealth from \$149/mo. The data is clear: the delivery method, not the molecule, is what unlocks the broader market.

JUL 23–24, 2026 · FDA ADVISORY PANEL

Panel backs 6 of 7 peptides under review — the next wave queuing up. Four of the six are already in TPPC formulations, on sale today.

ro

\$1.5B → \$5B → ~\$7B — Ro's valuation ladder in 19 months. Capital compounds fast here.

Hims & Hers revenue per public filings (2025 per company guidance); market cap as of August 2026. Filings via SEC EDGAR: sec.gov/edgar. Ro valuations per press reports and company announcements (2020–2022). Oral GLP-1 approvals per FDA and company announcements (Novo Nordisk, Dec 22, 2025; Eli Lilly, Apr 1, 2026). FDA Pharmacy Compounding Advisory Committee votes (July 23–24, 2026) are non-binding recommendations, not FDA approval; additions to the 503A Bulks List require separate rulemaking. Comparables differ materially from the Company; past performance of other companies is not a projection of the Company's future results.

Same playbook. Owned delivery IP. *Day-one pricing.*

TO SCALE — THE GAP IS THE OPPORTUNITY

circle area = market value

YOU ARE HERE

TPPC

~C\$24M · day one

CSE: BPC · C\$0.45

hims

\$6.7B

NYSE: HIMS

ro

~\$7B

last round · Feb 2022

~C\$24M

market cap at C\$0.45 · ~C\$27.0M fully diluted (52.7M shares,
Aug 21, 2026)

TPPC marker enlarged for
visibility.

THE RECEIPTS — ALREADY ON THE BOARD

High-margin DTC + subscription

Live · 7 products + patch

Nationwide telehealth Rx

Live · all 50 states

GLP-1 access

Rx today · patch in development

Patch purity, independently verified

95.5%

Exclusive MMA.INC audience

5M+ fans · 22 countries

Patch production run · July 2026

20,000 units received

National press

Featured in Men's Health

What none of them own

Proprietary delivery IP

Select comparables shown for market-context illustration only; they differ materially from the Company in scale, business model and risk. Sources: Hims & Hers Health, Inc. revenue and market capitalization per public filings and company guidance (sec.gov/edgar); Ro valuations per press reports and company announcements (2020–2022); Company market capitalization calculated on 52,731,207 common shares outstanding at C\$0.45 per share as at August 21, 2026 (approximately C\$27.0M fully diluted). Market data as of August 2026; private valuations as last reported. Comparable information was obtained from public sources and has not been independently verified by the Company. Past performance of other companies is not a projection of the Company's future results — see forward-looking statements and the note on comparables.

Operators, exits and *three decades of drug development.*

PS

Pratap Sandhu

CHIEF EXECUTIVE OFFICER

Public-company CEO leading TPPC's strategy and capital markets presence; trained in marketing & sales (BCIT) and experienced scaling consumer operations internationally.

JK

Justin Kirkland

CO-FOUNDER · CHIEF SCIENCE OFFICER

30+ years in drug development and delivery-system innovation; patent holder and architect of the Company's transdermal platform.

MS

Matt Stang

CO-FOUNDER · CHIEF VISIONARY OFFICER

Built and scaled culture-defining consumer media at High Times; brand and audience strategist for regulated categories.

BB

Barbara Branaman

CO-FOUNDER · PRINCIPAL INNOVATOR

Formulation innovator with clinical roots at BioReset Medical; drives the product-science pipeline.

NV

Nashir Virani

DIRECTOR

Built Golden Boy Foods to a US\$500M exit to Kraft; CEO of First Choice Foods — deep CPG scaling and M&A experience.

AB

Ajit Bhatti

DIRECTOR

19 years across technology and venture capital; governance and growth-capital perspective.

Peptides, *reimagined.*

CANADA

CSE: BPC

UNITED STATES

OTCQB: PNGAF

pratap@precisionpeptidecompany.com

precisionpeptidecompany.com

INVESTOR INFORMATION

CAPITAL STRUCTURE · AS AT AUGUST 2026

Issued & outstanding	52,731,207
Warrants	3,535,000
Options	3,833,334
Share price · market cap	C\$0.45 · ~C\$23.7M
Fully diluted	60,099,541

Forward-looking statements: Certain statements in this presentation constitute "forward-looking information" within the meaning of applicable Canadian securities legislation, including statements regarding product development, partnerships, market opportunity and business strategy. Such statements involve known and unknown risks and uncertainties; actual results could differ materially. Market and industry data are from third-party sources believed reliable but not independently verified. The Company undertakes no obligation to update such statements except as required by law. This presentation does not constitute an offer to sell or a solicitation to buy securities.

Not an offer of securities. This presentation has been prepared by The Precision Peptide Company (the “Company” or “Precision Peptide”) for informational purposes only. This presentation does not constitute or form part of, and should not be construed as, an offer to sell, or a solicitation of an offer to purchase or subscribe for, any securities of the Company in any jurisdiction, nor shall it or any part of it form the basis of, or be relied upon in connection with, any contract, commitment or investment decision whatsoever. This presentation is not a prospectus, offering memorandum, or other offering document under applicable securities laws of any jurisdiction.

Confidentiality and distribution. This presentation is confidential and is intended solely for the use of the person to whom it has been delivered. The information contained herein may not be reproduced, redistributed, or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose, without the prior written consent of the Company. By accepting this presentation, the recipient agrees to be bound by these confidentiality obligations.

Forward-looking statements. This presentation contains certain

“forward-looking statements” and “forward-looking information” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking statements”). All statements in this presentation, other than statements of historical fact, are forward-looking statements. Forward-looking statements include, but are not limited to, statements relating to: the Company’s corporate objectives and business strategy, including its positioning as a needle-free peptide delivery platform; the anticipated performance, applications, and consumer benefits of the Company’s proprietary transdermal delivery matrix and its extension across current and pipeline products; the development, testing, launch timing, and commercialization of products, including development-stage products with no assurance of completion or commercialization; the anticipated launch, capacity, and scale of the Casetides™ Peptide Pen and the Company’s nationwide telehealth and pharmacy compounding operations; the Company’s plans to expand its direct-to-consumer, subscription, omnichannel, and B2B licensing revenue channels; the anticipated benefits, scope, and duration of the Company’s exclusive marketing partnership with MMA.INC and related revenue-sharing arrangements; the anticipated size, growth, and evolution of global

wellness markets, and the Company’s positioning within them; the Company’s plans to establish, protect, and commercially utilize its intellectual property, including its proprietary delivery matrix; the Company’s capital structure, share price, and market capitalization, and any future financing plans and anticipated use of proceeds; and any other information as to the future plans and outlook for the Company.

Forward-looking statements are frequently identified by words and phrases such as “aims,” “anticipates,” “believes,” “continues to,” “designed for,” “estimates,” “expects,” “focused on,” “forecasts,” “future,” “guidance,” “in development,” “intends,” “may,” “might,” “objective,” “outlook,” “plans,” “potential,” “projected,” “pursue,” “reimagined,” “scheduled,” “seeks,” “should,” “strategy,” “targets,” “will,” “will be achieved,” “will occur,” or variations of such words and expressions, or statements that certain actions, events, or results “could,” “would,” or “might” occur. Forward-looking statements are based on the current expectations, estimates, assumptions, and beliefs of management as of the date of this presentation and are necessarily subject to a number of risks, uncertainties, and other factors.

Risks and uncertainties. Forward-looking statements are not guarantees of future performance. They involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation: the early-stage nature of the Company's product development activities and the uncertainties associated therewith; the risk that the Company's transdermal delivery technology may not achieve the anticipated bioavailability or performance characteristics described in this presentation; the ability to obtain, maintain, and enforce intellectual property rights in respect of the Company's proprietary delivery matrix and peptide formulations; the risk that the Company's products may be subject to additional or changed regulatory requirements; competition from companies with greater resources; the ability to realize the anticipated benefits of the Company's exclusive marketing partnership with MMA.INC, including the anticipated revenue-sharing arrangement; the availability of financing on acceptable terms; the impact of general economic and market conditions on consumer demand and the Company's ability

to raise capital; and other risk factors described in the Company's public filings available on SEDAR+ at www.sedarplus.ca.

The above list of risk factors is not exhaustive. Many of these uncertainties and contingencies can directly or indirectly affect, and could cause, actual results to differ materially from those expressed or implied in any forward-looking statements.

Readers and investors are cautioned not to place undue reliance on forward-looking statements, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements contained in this presentation are made as of the date of this presentation and are expressly qualified in their entirety by this cautionary note. Except as required by applicable Canadian securities laws or the policies of the Canadian Securities Exchange, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

For a complete description of the risks and uncertainties affecting the Company and its business, investors are directed to the

Company's continuous disclosure documents filed under the Company's profile on SEDAR+ at www.sedarplus.ca.

Comparables. Certain information presented herein compares Precision Peptide to other issuers and such data sets are considered to be "comparables". Comparable information about other issuers contained in this presentation was obtained from public sources and has not been independently verified by Precision Peptide. The comparables are considered to be an appropriate basis for comparison with Precision Peptide based on their industry, product mix, jurisdiction, size, operating scale and other additional criteria. The comparable issuers may face different risks from those applicable to Precision Peptide. Prospective investors are cautioned that there are risks inherent in making an investment decision based on the comparables and that the performance of Precision Peptide may be materially different from the comparable issuers. If the comparables contain a misrepresentation, investors do not have a remedy under securities legislation in any province of Canada. Prospective investors are cautioned to not put undue reliance on the comparables in making an investment decision.